Physician profile
William Wagner
NPI 1598738155
$22,237.48
in general payments reported to CMS, 2019-2025
43 companies · $37.79 in 2025
The $37.79 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $16K · 2020: $1,492 · 2021: $1,815 · 2022: $1,496 · 2023: $1,223 · 2024: $40.02 · 2025: $37.79.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,301.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,301.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $13,840.65 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $1,318.08 | 2019-2023 | |
| Emd Serono, INC. | $774.14 | 2019-2023 | Mavenclad |
| Amgen INC. | $555.70 | 2019-2023 | Aimovig |
| Mdd US Operations, LLC | $545.89 | 2019 | |
| Biogen, INC. | $472.82 | 2019-2023 | Vumerity, Tysabri |
| Mallinckrodt Hospital Products INC. | $457.64 | 2020-2022 | |
| Abbvie INC. | $445.44 | 2021-2023 | Botox, Qulipta, Ubrelvy |
| Alexion Pharmaceuticals, INC. | $398.12 | 2019-2023 | Ultomiris |
| Ucb, INC. | $396.74 | 2019-2023 | Briviact |
| Celgene Corporation | $275.05 | 2021-2023 | Zeposia |
| Lilly USA, LLC | $264.73 | 2019-2023 | Reyvow, Emgality |
| Allergan, INC. | $232.43 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $221.77 | 2020-2022 | |
| Sunovion Pharmaceuticals INC. | $201.62 | 2019-2021 |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Wagner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.